--> PerkinElmer - Cisbio Home Life sciences NASH / Fibrosis NASH / NAFLD Discover the cutting edge of NAFLD knowledge NASH (non-alcoholic steatohepatitis), NAFLD (non-alcoholic fatty liver disease), and fibrosis are a set of liver pathologies that have been rising for the past decades and are now on the verge of growing into a global epidemy. They stem from the accumulation of fat in the liver, which is the first and reversible event to occur within the physio-pathological progression from a healthy liver to NASH. This abnormal and significant lipid accumulation in the liver, referred to by the terms hepatic steatosis, Simple Steatosis (SS) or (Non-Alcoholic) Fatty Liver (NAFL), is the result of a dramatic increase of free fatty acid fluxes into the organ. This condition is understood to arise from mis-regulation of portions of the lipid metabolism including lipogenesis, beta-oxidation mechanisms and the whole export/uptake/storage axis. Progression steps from healthy liver to of NAFLD & NASH related pathologies Cisbio has developed a panel of ready-to-use assays to monitor biomarkers, phosphoproteins and transcription factors involved in the development and progression of NASH, NAFLD and fibrosis. In addition to our commitment to develop the best possible tools for your research, we also provide guidelines, tips, data and various content on NASH. Guides, Infographics, application notes dedicated to NASH are now at your fingertips! Guide A 360° review of NAFLD pathways Download now On-demand Webinar NASH – Fibrosis Research and Drug Discovery Watch now Non-alcoholic fatty liver Next Non-alcoholic fatty liver Accumulation of fat in the liver is the first and reversible event that occurs within the physio-pathological progression from a healthy liver to NASH. This abnormal and significant lipid accumulation in the liver, referred to by the terms hepatic steatosis, Simple Steatosis (SS) or (Non-Alcoholic) Fatty Liver (NAFL), is the result of a dramatic increase of free fatty acid fluxes into the organ. This condition is understood to arise from mis-regulation of portions of the lipid metabolism including lipogenesis, beta-oxidation mechanisms and the whole export/uptake/storage axis. Cisbio has developed a panel of ready-to-use assays to monitor biomarkers, phosphoproteins and transcription factors involved in the steps leading to Hepatic Steatosis. Infographic NAFLD: 1 min to understand the next global epidemic Download now Hepatic Steatosis is linked to mis-regulations in the metabolsim of fat. Unchecked activation of lipogenesis, beta-oxidation and misdirection in fat storage, uptake and export contribute to fat accumulation in droplets that characterize steatosis. These mis-regulations are often linked to defects in insulin signaling, which regulates the management of lipid droplets lipophagy via mTOR complexes. Hepatocyte Next Phospho-MKK4 (Ser257) cellular kit Total ACC Cellular Kit Cleaved PARP (Asp214) Cellular Kit HMGB1 kit Human CTGF Kit Phospho-ACC (Ser79) cellular kit Phospho-AMPK (Thr172) cellular kit Phospho-BAD (Ser112) cellular kit Phospho-CREB (Ser133) cellular kit Phospho-EIF2 alpha (Ser52) cellular kit Phospho-IRS1 (Ser307 mouse/Ser312 human) cellular kit Total AMPK cellular kit Total CREB cellular kit Total EIF2 alpha cellular kit Total IRS1 cellular kit See all products PerkinElmer - Cisbio Get on the list to receive remarkable content Subscribe Life sciences In Vitro Diagnostic Cisbio Select your country Follow us This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. OK, accept all Deny all cookies Personalize Privacy policy